Format

Send to

Choose Destination
Head Neck. 2019 Jan;41(1):185-197. doi: 10.1002/hed.25471. Epub 2018 Dec 14.

Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance.

Author information

1
Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India.
2
Centre for Applied Chemistry, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India.
3
Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu, India.

Abstract

BACKGROUND:

Bax, a proapoptotic protein but its regulation during oral cancer progression and resistance remains elusive.

METHODS:

A total of 127 samples including adjacent normal, primary tumor, and resistance to chemoradiation therapy (RCRT) samples from oral squamous cell carcinoma (OSCC) patients were used. The status of Bax was analyzed at DNA/mRNA/protein levels and the results were correlated with p53 and Akt expression in tissue samples/cisplatin-resistant oral tongue SCC (SCC9/SCC4-CisR) cell line.

RESULTS:

Frequent progressive decrease of Bax expression with infrequent promoter methylation, polymorphisms G(-248)A, and mutations was observed in OSCC progression/resistance. Furthermore, by targeting Akt pathway, induction of Bax-dependent cell death was observed and this was further enhanced with nimbolide treatment in SCC9/SCC4-CisR cells.

CONCLUSION:

Hence, the Bax gene alteration and its deregulation through p53/Akt pathway are important for OSCC progression and drug resistance. Akt Inhibitor VIII and nimbolide synergistically induce Bax, and it is therefore beneficial for chemosensitizing cisplatin-resistant human OSCC.

KEYWORDS:

Akt; Bax; Bcl-2; GSK3α; GSK3β; OSCC; chemoradiation resistance; drug resistance; oral cancer; oral squamous cell carcinoma; p53

PMID:
30549344
DOI:
10.1002/hed.25471

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center